Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The offer is the latest in a series of deals by Concentra, an investment vehicle controlled by Tang Capital Partners, to buy ...

A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...